202 related articles for article (PubMed ID: 35710591)
1. Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer.
Chaudhary KR; Kinslow CJ; Cheng H; Silva JM; Yu J; Wang TJ; Hei TK; Halmos B; Cheng SK
Sci Rep; 2022 Jun; 12(1):10140. PubMed ID: 35710591
[TBL] [Abstract][Full Text] [Related]
2. Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells.
Cheng H; Zhang Z; Rodriguez-Barrueco R; Borczuk A; Liu H; Yu J; Silva JM; Cheng SK; Perez-Soler R; Halmos B
Oncotarget; 2016 May; 7(20):28976-88. PubMed ID: 26716514
[TBL] [Abstract][Full Text] [Related]
3. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
4. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway.
Huang G; Lou T; Pan J; Ye Z; Yin Z; Li L; Cheng W; Cao Z
Aging (Albany NY); 2019 Apr; 11(7):2138-2150. PubMed ID: 30981205
[TBL] [Abstract][Full Text] [Related]
5. Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study.
Baghbani E; Noorolyai S; Rahmani S; Shanehbandi D; Shadbad MA; Aghebati-Maleki L; Mokhtarzadeh A; Brunetti O; Fasano R; Silvestris N; Baradaran B
Biomed Pharmacother; 2022 Jan; 145():112370. PubMed ID: 34862113
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
7. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
Cheng H; Zhang Z; Borczuk A; Powell CA; Balajee AS; Lieberman HB; Halmos B
Carcinogenesis; 2013 Apr; 34(4):739-49. PubMed ID: 23275151
[TBL] [Abstract][Full Text] [Related]
8. FBW7 upregulation enhances cisplatin cytotoxicity in non- small cell lung cancer cells.
Yu HG; Wei W; Xia LH; Han WL; Zhao P; Wu SJ; Li WD; Chen W
Asian Pac J Cancer Prev; 2013; 14(11):6321-6. PubMed ID: 24377525
[TBL] [Abstract][Full Text] [Related]
9. CUEDC1 inhibits epithelial-mesenchymal transition via the TβRI/Smad signaling pathway and suppresses tumor progression in non-small cell lung cancer.
Cui Y; Song Y; Yan S; Cao M; Huang J; Jia D; Liu Y; Zhang S; Fan W; Cai L; Li C; Xing Y
Aging (Albany NY); 2020 Oct; 12(20):20047-20068. PubMed ID: 33099540
[TBL] [Abstract][Full Text] [Related]
10. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
[TBL] [Abstract][Full Text] [Related]
11. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of basic fibroblast growth factor increases cisplatin sensitivity in A549 non-small cell lung cancer cells.
He L; Meng Y; Zhang Z; Liu Y; Wang X
J Cancer Res Ther; 2018; 14(7):1519-1524. PubMed ID: 30589033
[TBL] [Abstract][Full Text] [Related]
13. Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC).
Li ZH; Qiu MZ; Zeng ZL; Luo HY; Wu WJ; Wang F; Wang ZQ; Zhang DS; Li YH; Xu RH
J Transl Med; 2012 Feb; 10():21. PubMed ID: 22304828
[TBL] [Abstract][Full Text] [Related]
14. GPR78 Regulates Autophagy and Drug Resistance in Non-small Cell Lung Cancer.
Liao X; Cai R; Li G; Chen F
Altern Ther Health Med; 2023 Jan; 29(1):130-136. PubMed ID: 35986740
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells.
Yu G; Zhong N; Chen G; Huang B; Wu S
Tumour Biol; 2014 Oct; 35(10):10341-9. PubMed ID: 25038915
[TBL] [Abstract][Full Text] [Related]
16. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
Qi MM; Ge F; Chen XJ; Tang C; Ma J
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of miR-15b partially reverses the cisplatin resistance of NSCLC through the GSK-3β/MCL-1 pathway.
Lu T; Lu W; Jia C; Lou S; Zhang Y
Adv Clin Exp Med; 2021 Aug; 30(8):849-857. PubMed ID: 34286518
[TBL] [Abstract][Full Text] [Related]
18. PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response.
Tian FM; Zhong CY; Wang XN; Meng Y
Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2635-2641. PubMed ID: 28678321
[TBL] [Abstract][Full Text] [Related]
19. TRIM17-mediated ubiquitination and degradation of RBM38 promotes cisplatin resistance in non-small cell lung cancer.
Zhong T; Zhang J; Liu X; Li H
Cell Oncol (Dordr); 2023 Oct; 46(5):1493-1507. PubMed ID: 37219768
[TBL] [Abstract][Full Text] [Related]
20. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
He Y; Xie H; Yu P; Jiang S; Wei L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
